How Photonics Developers Are Bolstering the World’s Most Important Research

Among the predictions for 2018, are a series of scientific breakthroughs including from, many of which involve optics, lasers and other light sources, otherwise known as photonics.

It’s an advanced field, that’s powering much of the world’s most important research, from scanning bodies in a search for cures to the body’s most troubling ailments, to the search for the origins of life itself.

As scientists celebrate the fruits of their research, so too do the photonics and imaging developers of the technology used by the scientists, including ASML Holding N.V. (NASDAQ: ASML), Coherent, Inc. (NASDAQ: COHR), Hologic, Inc. (NASDAQ: HOLX), IPG Photonics Corporation (NASDAQ: IPGP), and Zecotek Photonics Inc (TSX.V: ZMS) (OTC: ZMSPF).

According to a report by Research and Markets, the photonics market is projected to grow from $530.52 billion in 2017 to $795.54 billion in 2022.

Overall, optics and laser companies had a record-breaking year in 2017—with spending on equipment in the sector surpassing an annual mark that has stood since 2000.

Significant breakthroughs are happening across the entire photonics sector, and within the surge the sector has created and sustained several multi-billion-dollar companies, including ASML Holding N.V. (NASDAQ: ASML), Coherent, Inc. (NASDAQ: COHR) and IPG Photonics Corporation (NASDAQ: IPGP).

Now there are openings for junior photonics developers like Zecotek Photonics Inc (TSX.V: ZMS) (OTC: ZMSPF) to catch up some ground.

Zecotek has already made strides in the right direction, with key partnerships spanning from their proprietary crystals being used in both CERN’s Large Hadron Collider (LHC) and the world’s first full-body PET scanner, to developing 3D head-up displays (HUDs) with two major European automakers.


Probably the most notable of Zecotek’s roles in major research is their technology being used in the search for the origin-mechanics of the universe—questions that when answered could be the largest contribution to humankind… ever!

Back in 2012, scientists at CERN using the Large Hadron Collider (LHC) reported that they observed a particle “consistent with the long-sought Higgs boson.”

But that wasn’t even close to the end goal of the project—the LHC is just getting started.

In fact, last summer CERN announced it will build a particle collider that’s three times as big as the LHC and seven times more powerful.

Through a relationship that started in 2014, Zecotek’s LFS crystals found a home in CERN’s Compact Muon Solenoid (CMS) experiment—one of the largest international scientific collaborations in history. It was a major vote of confidence for Zecotek to have their LFS crystals involved in the world’s most precise particle detection.

By the same year that Zecotek’s technology had been brought on bard, the CMS experiment had involved 4,300 particles physicists, engineers, technicians, students, and support staff, from 42 countries.

Zecotek provides LFS crystals required for the CMS experiment as they had the necessary energy resolution and radiation hardness,” says Professor Brad Cox, Leader of the University of Virginia, CERN’s Compact Muon Solenoid experiment, led by the University of Virginia. “In using the thin LFS crystal plates [our] team were able to reduce the technical and cost risks associated with measurements in such experiments.”

The Zecotek LFS crystal is quickly being recognized as a world-class photonics technology—However, it’s just one of Zecotek’s 50+ patented, and patent-pending technologies.


Equipped with over 560,000 detector elements, the UC Davis-based EXPLORER scanner is designed and ready to make some of the biggest breakthroughs ever recorded in the field of clinical diagnostics.

“A system with this detection sensitivity will dramatically improve our ability to study cancer and other diseases as well as advance diagnostic capabilities in our industry,” said lead researcher Simon Cherry, Head of Cherry Labs, and professor in the UC Davis Department of Biomedical Engineering.

The EXPLORER technology fits within the growing Biophotonics Market which is projected to grow at a CAGR of 11.5% through 2020 to $50.18 billion.

Zecotek already has three key patent-protected and proprietary technologies with the potential to revolutionize the $15 billion medical diagnostics industry: LFS Scintillation Crystals; Solid-State MAPD Photo Detectors and Transistors; and Integrated Detector Modules (IDM).

Much like the futuristic sick bay on Star Trek’s USS Enterprise, the EXPLORER can view all organs of the body simultaneously, with a 40-fold increase in effective signal over current technology.

Positron emission tomography (PET) is widely considered the most sensitive technique available to safely study metabolism, physiology, and molecular pathways in the living human being.

Total-body PET has the potential to completely revolutionize clinical diagnostics, and the understanding and treatment of disease through analysis of better imaging data from the whole body.

Trusted by the developers of the EXPLORER scanner, it was Zecotek’s proprietary LFS scintillation crystals they employed in the technology—based on the crystals’ renowned quality and effectiveness in their application.

Zecotek provided Cherry labs with a selection of scintillation crystals from their patented LFS-3 range. After preliminary testing Cherry labs found the crystals to have the fast decay constant they required, enhancing results for their depth-encoded PET detector designs,” added Simon Cherry of UC Davis. “This combined with the competitive pricing Zecotek is able to offer made for an ideal solution.”

Official delivery of the prototype EXPLORER scanner is expected later this year.

On top of the UC Davis order, Zecotek secured an order worth $1.2 million for their patented LFC scintillation crystals with EBO optoelectronics.

Should the prototype meet and surpass its technological goals, scanners of this magnitude could very quickly be purchased and installed in other hospitals and university research facilities around the world.

As research gains are made, so too will gains be made by companies powering that research with their technological advancements, like Zecotek Photonics Inc (TSX.V: ZMS) (OTC: ZMSPF).



Founded in 1974, ASML develops, produces, markets, sells, and services advanced semiconductor equipment systems with a focus on lithography related systems.

Coherent, Inc. (NASDAQ: COHR)

Founded in 1966, Coherent provides lasers and laser-based technology in a range of scientific, commercial, and industrial applications worldwide, through two segments, Specialty Lasers and Systems, and Commercial Lasers and Components.

Hologic, Inc. (NASDAQ: HOLX)

Founded in 1985, Hologic develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

IPG Photonics Corporation (NASDAQ: IPGP)

Founded in 1990, IPG Photonics develops and manufactures a range of high-performance fiber lasers, fiber amplifiers, and diode lasers used in various applications, primarily in materials processing worldwide.

For a more in-depth look into ZMS you can view the in-depth report at USA News Group:

American News Group 

Legal Disclaimer/Disclosure

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter/report/commentary piece/article is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Furthermore, it is certainly possible for errors or omissions to take place regarding the profiled company, in communications, writing and/or editing.

Nothing in this publication should be considered as personalized financial advice. We are not licensed under any securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. American News group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Zecotek Photonics Inc. advertising and digital media from the company. There may be 3rd parties who may have shares of Zecotek Photonics Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. The owner/operator of MIQ intends has purchased shares of Zecotek Photonics Inc. through a private placement and does not intend on selling any shares within 72 hours of this updated publication date (February 8, 2018) after such point we reserve the right to buy and sell shares in the open market, no further notice will be given.

By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing MIQ, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.